MYRIAD GENETICS INC's ticker is MYGN and the CUSIP is 62855J104. A total of 203 filers reported holding MYRIAD GENETICS INC in Q2 2021. The put-call ratio across all filers is 0.66 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $1,856,000 | -8.6% | 60,931 | -40.6% | 0.01% | 0.0% |
| Q4 2020 | $2,030,000 | +28.2% | 102,644 | -15.4% | 0.01% | +27.3% |
| Q3 2020 | $1,583,000 | +96.2% | 121,344 | +70.6% | 0.01% | +83.3% |
| Q2 2020 | $807,000 | +0.5% | 71,144 | +26.7% | 0.01% | -14.3% |
| Q1 2020 | $803,000 | -44.1% | 56,144 | +6.4% | 0.01% | -30.0% |
| Q4 2019 | $1,436,000 | -12.4% | 52,744 | -7.9% | 0.01% | 0.0% |
| Q3 2019 | $1,639,000 | -2.4% | 57,244 | -5.3% | 0.01% | -9.1% |
| Q2 2019 | $1,679,000 | +135.8% | 60,444 | +182.0% | 0.01% | +120.0% |
| Q1 2019 | $712,000 | +18.3% | 21,431 | +3.4% | 0.01% | 0.0% |
| Q4 2018 | $602,000 | -40.0% | 20,731 | -4.9% | 0.01% | -37.5% |
| Q3 2018 | $1,003,000 | +11.3% | 21,802 | -9.5% | 0.01% | +33.3% |
| Q2 2018 | $901,000 | +23.9% | 24,102 | -2.0% | 0.01% | +20.0% |
| Q1 2018 | $727,000 | – | 24,602 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 5,000,000 | $90,850,000 | 3.94% |
| Altium Capital Management LP | 221,000 | $4,016,000 | 1.61% |
| DISCIPLINED GROWTH INVESTORS INC /MN | 1,900,787 | $34,537,000 | 0.93% |
| Zebra Capital Management LLC | 15,352 | $279,000 | 0.82% |
| PFM Health Sciences, LP | 1,177,250 | $21,391,000 | 0.82% |
| EARNEST PARTNERS LLC | 6,462,138 | $117,417,000 | 0.78% |
| Glenview Capital Management | 1,696,791 | $30,831,000 | 0.77% |
| AIMZ Investment Advisors, LLC | 42,085 | $765,000 | 0.37% |
| Phocas Financial Corp. | 127,949 | $2,325,000 | 0.35% |
| Redhawk Wealth Advisors, Inc. | 34,680 | $630,000 | 0.29% |